Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Raw Materials of $30.7 million for Q1 2026, up 1661.04% year-over-year from $1.7 million in Q1 2025, and up 5.75% quarter-over-quarter from $29.0 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $30.7 million for Q1 2026.
- In Q1 2026, Raw Materials rose 1661.04% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $30.7 million (up 1661.04% YoY), while the FY2025 annual figure was $29.0 million, changed N/A from the prior year.
- Raw Materials for Q1 2026 stood at $30.7 million, up from $29.0 million in the prior quarter.
- The five-year high for Raw Materials was $30.7 million in Q1 2026, with the low at $1.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.20 Mn |
| Mar 31, 2026 | 30.70 Mn |
| Dec 31, 2025 | 29.03 Mn |
| Sep 30, 2025 | 21.40 Mn |
| Jun 30, 2025 | 14.18 Mn |
| Mar 31, 2025 | 1.74 Mn |